TU2218Pembrolizumabanti PD-(L)1 antibodyECOG Performance StatusHNSCChead and neck squamous cell carcinoma (HNSCC)
…ynx (25%), oral cavity (16.7%), hypopharynx (16.7%).Conclusions TU2218 in combination with Pembrolizumab in patients with HNSCC demons…